Tonix Pharmaceuticals Holding Corp. recently highlighted its current clinical and commercial activities in a presentation. The company is focused on developing therapeutics for conditions involving pain, neurology, psychiatry, and addiction, as well as areas like immunology, infectious diseases, and rare diseases. Their key clinical program, TNX-102 SL, is being developed for fibromyalgia, with an FDA decision on marketing authorization expected by August 15, 2025. The program has been granted FDA Fast Track Designation, and potential product launch is anticipated for 2025. Additionally, Tonix is advancing TNX-1500, an anti-CD40L monoclonal antibody, for organ transplant rejection and autoimmune conditions, having completed a Phase 1 study. The company is also marketing products like Zembrace® and Tosymra® for acute migraine treatment. You can access the full presentation through the link below.